Multiple myeloma is the hematological malignancy, characterized by plasma cell bone marrow infiltration and end-organ involvement. SMM is an intermediate clinical entity between MGUS and MM, with a risk of progression to symptomatic disease. Bone disease is the most frequent symptom of MM, as most patients are observed to be developing bone lesions throughout their disease course. Therefore, imaging as a diagnostic technique plays a crucial role in the diagnosis and management of the disorder. WBLDCT is widely available and has been incorporated in the latest diagnostic criteria of the IMWG. The main aim of the study was to evaluate the role of WBLDCT in the early identification of lesions in patients with SMM who progress solely with bone disease.100 asymptomatic patients in total were consecutively assessed with WBLDCT at baseline, 12 months after diagnosis, and every 1 year thereafter. 10 percent of patients were identified as progressors with this single imaging modality.
The findings of this study were successful in evaluating prospective patients with SMM at different time points to identify early bone lesions related to MM evolution.
Reference: https://www.nature.com/articles/s41408-020-00360-9
